Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
AddLife ABADDLF 80 3-Year EBITDA Growth Rate is 7.60% as of Jun. 2026, which is 64% below its 10-year median of 21.35. GuruFocus rates ADDLF with a GF Score™ of 80/100 and a GF Value™ of $14.61. The stock has 5 warning signs investors should review. Among 692 Medical Devices & Instruments companies, AddLife AB ranks worse than 50.43% on this metric.
During the past 12 months, AddLife AB's average EBITDA Per Share Growth Rate was 31.50% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 7.60% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 8.60% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 29.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of AddLife AB was 66.80% per year. The lowest was 0.70% per year. And the median was 21.35% per year.
AddLife AB (OTCPK:ADDLF) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
AddLife AB 3-Year EBITDA Growth Rate Related Terms
ADDLF vs ISRG, BDX, MDLN: 3-Year EBITDA Growth Rate Comparison
For the Medical Instruments & Supplies subindustry, AddLife AB's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AddLife AB 3-Year EBITDA Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, AddLife AB's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where AddLife AB's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 7.60% mean?
AddLife AB (ADDLF) has a 3-Year EBITDA Growth Rate of 7.60% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for AddLife AB and its competitors. This is 64% below median its historical median of 21.35. Over the past decade, AddLife AB's 3-Year EBITDA Growth Rate has ranged from 0.70 to 66.80. According to the industry distribution chart, AddLife AB ranks #349 out of 692 companies in the Medical Devices & Instruments industry, placing it in the top 50.4%.
Is AddLife AB's 3-Year EBITDA Growth Rate too high?
AddLife AB's current 3-Year EBITDA Growth Rate of 7.60% is 64% below median its 10-year median of 21.35. Over the past 10 years, this metric has ranged from a low of 0.70 to a high of 66.80. The Medical Devices & Instruments industry median 3-Year EBITDA Growth Rate is 8.20. AddLife AB's value of 7.60% is 7.3% below this industry median. Based on the distribution chart, AddLife AB ranks #349 out of 692 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, AddLife AB has a GF Score™ of 80/100, reflecting its overall financial health beyond just this single metric.
How does AddLife AB's 3-Year EBITDA Growth Rate compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, AddLife AB ranks #349 out of 692 companies for 3-Year EBITDA Growth Rate. This places AddLife AB in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 8.20. AddLife AB's value of 7.60% is 7.3% below this benchmark. Historically, AddLife AB's own 3-Year EBITDA Growth Rate has ranged from 0.70 to 66.80 over the past decade. While the company's 10-year median is 21.35 vs. the industry median of 8.20, AddLife AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Devices & Instruments company?
The median 3-Year EBITDA Growth Rate among Medical Devices & Instruments companies is 8.20, based on 692 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. AddLife AB's current 3-Year EBITDA Growth Rate of 7.60% is 7.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for AddLife AB and its competitors. For the Medical Devices & Instruments industry, the median 3-Year EBITDA Growth Rate is 8.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AddLife AB's current 3-Year EBITDA Growth Rate is 7.60%, which is 64% below median its own 10-year median of 21.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AddLife AB stock overvalued right now?
AddLife AB (ADDLF) has a current 3-Year EBITDA Growth Rate of 7.60%. The stock's GF Value™ is $14.61, compared to a current price of $15.75 — trading 7.8% above its estimated fair value. The current 3-Year EBITDA Growth Rate is 7.60%, which is 64% below median its 10-year median of 21.35 and 7.3% below the Medical Devices & Instruments industry median of 8.20. AddLife AB's overall GF Score™ is 80/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For AddLife AB (ADDLF), the current 3-Year EBITDA Growth Rate is 7.60% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is AddLife AB (ADDLF) Overvalued in 2026?
Based on GuruFocus' analysis, AddLife AB stock appears to be overvalued.
The current stock price of $15.75 is trading 7.8% above its estimated GF Value™ of $14.61.
Key valuation signals for ADDLF:
3-Year EBITDA Growth Rate: 7.60% (64% below median its 10-year median of 21.35)
GF Value™: $14.61 vs. price of $15.75 (7.8% above fair value)
Industry Position: 7.3% below the Medical Devices & Instruments median (#349 of 692)
No single metric tells the full story. See the ADDLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
AddLife AB is engaged in the business of providing products, services, and advisory services. The company operates in two segments: Labtech and Medtech. The Labtech segment provides analytical instruments, equipment, microscopes, consumables, and reagents, as well as software support and technical service to laboratories in medicine, research, academia and the food and pharmaceutical industries. The Medtech segment includes a range that spans from basic consumables to instruments for surgical procedures, welfare technology, and assistive devices for the elderly and disabled. The majority of revenue is derived from the Medtech segment.
80GF Score
Get the complete analysis for ADDLF
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ADDLF has been successfully added to your 
